I personally don't think we have seen much institutional interest up to this point and that it's been mostly retail-
The CMS approval was a given but the pricing announced today was very favorable IMO. I expected us to rally or at a minimum end in the green today. The product 'should be' a game-changer AND the team(money) behind this is about as good as one could wish for IMO.
'If' it's just retail capitulation, we should be close now(?) Those in cheap are jumping out while they still have profits and those in high are bailing to save what's left. For those of us who see the bigger picture and are here for the medium-long term, 'I think' it's just a matter of time. My entire position is in the warrants as I fully expect DMTK to be 'over' $30 by 2024.
Time will tell...
Good Luck!!
-------------------------------------------------------------------
All posts are strictly my opinion and are not buy or sell recommendations.
Recent DMTK News
- DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology • Business Wire • 03/08/2024 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 01:04:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 01:01:56 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/07/2024 09:17:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 09:53:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:05:52 PM
- DermTech Reports Fourth-Quarter 2023 Financial Results • Business Wire • 02/29/2024 09:01:00 PM
- DermTech Announces Release Date for Fourth-quarter 2023 Financial Results • Business Wire • 02/13/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 09:32:21 PM
- DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations • Business Wire • 01/31/2024 09:30:00 PM
- DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types • Business Wire • 01/18/2024 01:05:00 PM
- DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay • Business Wire • 01/16/2024 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 12:16:22 AM
- DermTech Announces Positive Topline Results From Trust 2 Study Evaluating the DermTech Melanoma Test (DMT) • Business Wire • 01/08/2024 01:00:00 PM
- DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 12/14/2023 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/12/2023 01:02:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/12/2023 01:02:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/12/2023 01:01:22 AM
- The Gross Law Firm Notifies Shareholders of DermTech, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 15, 2023 - (NASDAQ: DMTK) • PR Newswire (US) • 12/04/2023 10:45:00 AM
- The Gross Law Firm Notifies Shareholders of DermTech, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 15, 2023 - (NASDAQ: DMTK) • PR Newswire (US) • 11/28/2023 10:45:00 AM
- The Gross Law Firm Notifies Shareholders of DermTech, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 15, 2023 - (NASDAQ: DMTK) • PR Newswire (US) • 11/21/2023 10:45:00 AM
- The Gross Law Firm Notifies Shareholders of DermTech, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 15, 2023 - (NASDAQ: DMTK) • PR Newswire (US) • 11/14/2023 10:45:00 AM
- The Gross Law Firm Notifies Shareholders of DermTech, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 15, 2023 - (NASDAQ: DMTK) • PR Newswire (US) • 11/07/2023 06:57:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/02/2023 08:31:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 08:09:16 PM
FEATURED Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market • Mar 18, 2024 8:51 AM
FEATURED Prospera Energy Inc. Announces a 508% increase in the 2023 Proven Developed Producing (PDP) Reserve Valuation • Mar 18, 2024 8:09 AM
Greenlite Ventures Enters into Strategic Alliance with Woodway USA • GRNL • Mar 15, 2024 4:00 PM
HealthLynked Welcomes David Rosal as New Chief Financial Officer • HLYK • Mar 13, 2024 8:00 AM
ECGI Holdings, Inc. Announces Continued Efforts in Financial Optimization • ECGI • Mar 13, 2024 8:00 AM
PSYC Begins Business Overhaul Process with Consolidation of 10 Previously Issued Convertible Debentures • PSYC • Mar 13, 2024 7:13 AM